Tradestie Institutional Equity Comparison Engine
PRTO vs AKTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AKTX Overall Edge
AKTX Captures Institutional Edge (2โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akari Therapeutics plc ADR (0.01 USD) (AKTX) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, PRTO trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus AKTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PRTO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AKTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
PRTO N/M vs AKTX N/M Fwd P/E
Growth & Margin Winner
AKTX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
AKTX
1Y -3.4% vs +1339.7% ยท 52W Pos 0% vs 24%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
PRTO
US Equity
PRTO
Institutional Equity
$24.45
-3.36% 1D
Market Cap
N/A
1M Return
-9.56%
1Y Return
-3.39%
Forward P/E
N/M
Unified AI Score
33.3 / 100
SELL
Tech 12.0
Fund 36.0
Flow 50.0
Mom 34.0
AKTX
NASDAQ
Akari Therapeutics plc ADR (0.01 USD)
Pharmaceutical Preparations
$7.18
+7.0% 1D
Market Cap
$15.6M
1M Return
-11.36%
1Y Return
+1339.74%
Forward P/E
N/M
Unified AI Score
50.1 / 100
HOLD
Tech 65.0
Fund 56.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PRTO -3.39%
AKTX +1339.74%
Spread: +5159.61 pp (AKTX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
PRTO TTM Op. Margin: N/A
AKTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PRTO vs AKTX. Trailing 12-month operating profitability (PRTO N/A vs AKTX 0.0%) and valuation multiples (PRTO N/M vs AKTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PRTO | AKTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $15.6M | Larger Scale | AKTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | AKTX |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | AKTX |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | AKTX |
| Return on Equity (ROE) Capital Efficiency | N/A | -146.3% | Higher ROE | AKTX |
| 52-Week Range Position Momentum | 0% ($24โ$29) | 24% ($0โ$29) | Stronger Trend | AKTX |
| Beta / 30D Volatility Risk Regime | 0.89ฮฒ ยท 21% Vol | 77.35ฮฒ ยท 143% Vol | Lower Realized Risk | PRTO |
| Unified Institutional Score Composite Signal | 33.3 / 100 (SELL) | 50.1 / 100 (HOLD) | Higher Composite | AKTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PRTO vs AKTX Buy Guide
PRTO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
AKTX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PRTO nor AKTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.